929 POSTER Pre-operative selection criteria for operability in recurrent ovarian cancer. a study of the AGO organkommission ovar and the AGO ovarian cancer study group (AGO-OVAR)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81224-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 267-268

Keyword(s):

Ovarian Cancer ◽

Selection Criteria ◽

Recurrent Ovarian Cancer ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

Download Full-text

Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5004 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5004-5004 ◽

Author(s):

P. Harter ◽

G. P. Breitbach ◽

B. Tanner ◽

J. Sehouli ◽

V. Heilmann ◽

...

Keyword(s):

Ovarian Cancer ◽

Selection Criteria ◽

Recurrent Ovarian Cancer ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

Download Full-text

39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90073-5 ◽

2003 ◽

Vol 1 (5) ◽

pp. S16 ◽

Author(s):

S. Loibl ◽

W. Meier ◽

A. du Bois ◽

W. Kuhn ◽

J. Pfisterer ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group ◽

Phase Iii Study

Download Full-text

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70319-1 ◽

2007 ◽

Vol 2007 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

Cancer Study ◽

Cancer Study Group ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70326-9 ◽

2007 ◽

Vol 2007 ◽

pp. 77-78

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group ◽

Phase Iii Study

Download Full-text

Prognostic Factors for Complete Debulking in Advanced Ovarian Cancer and Its Impact on Survival: An Exploratory Analysis of a Prospectively Randomized Phase III Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

Obstetrical & Gynecological Survey ◽

10.1097/01.ogx.0000287604.22654.20 ◽

2007 ◽

Vol 62 (11) ◽

pp. 719-720

Author(s):

Pauline Wimberger ◽

Nils Lehmann ◽

Rainer Kimmig ◽

Alexander Burges ◽

Werner Meier ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Advanced Ovarian Cancer ◽

Exploratory Analysis ◽

Phase Iii ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group ◽

Impact On Survival ◽

Phase Iii Study

Download Full-text

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.02.026 ◽

2007 ◽

Vol 106 (1) ◽

pp. 69-74 ◽

Author(s):

Pauline Wimberger ◽

Nils Lehmann ◽

Rainer Kimmig ◽

Alexander Burges ◽

Werner Meier ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Advanced Ovarian Cancer ◽

Exploratory Analysis ◽

Phase Iii ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group ◽

Impact On Survival ◽

Phase Iii Study

Download Full-text

172 Phase I/II study of PLD and carboplatin in patients with advanced gynaecological carcinomas. An interim analysis of the GYN II trial of the AGO ovarian cancer study group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90205-9 ◽

2003 ◽

Vol 1 (5) ◽

pp. S55

Author(s):

V. Heilmann ◽

A. Burges ◽

M. Gropp ◽

J. Pfisterer ◽

B. Schmalfeldt ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Interim Analysis ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

Download Full-text

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.10.053 ◽

2007 ◽

Vol 105 (1) ◽

pp. 132-137 ◽

Author(s):

U WAGNER ◽

A DUBOIS ◽

J PFISTERER ◽

J HUOBER ◽

S LOIBL ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

Download Full-text

Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5016 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5016-5016

Author(s):

S. Loibl ◽

A. Du Bois ◽

J. Pfisterer ◽

J. Huober ◽

H.-J. Lueck ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

Download Full-text

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90070-x ◽

2003 ◽

Vol 1 (5) ◽

pp. S15 ◽

Author(s):

E. Pujade-Lauraine ◽

J. Pfisterer ◽

A. Lortholary ◽

R. Kimmig ◽

B. Weber ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Study Group ◽

Line Treatment ◽

Phase Iii Trial ◽

Cancer Study ◽

Cancer Study Group ◽

Gynaecologic Cancer ◽

First Line Treatment

Download Full-text